IMAC Holdings, Inc.
IMAC Holdings, Inc. is a U.S.-based specialty healthcare and life sciences company that now operates primarily through Ignite Proteomics, LLC. Ignite uses a patented RPPA proteomics platform to measure protein signaling and support oncology treatment decisions and biopharmaceutical drug development, while the legacy IMAC clinical operations remain part of the consolidated structure.
Fiscal year 2024 · change from previous year
Development 2019–2024
Business
Share of revenueRPPA-based laboratory testing that quantifies protein signaling for cancer care and research.
Analytical services used by drug developers for biomarker and translational research.
Legacy outpatient and rehabilitation services billed to patients and third-party payers.
Customers
The company sells primarily to oncology clinicians, hospitals, and biopharmaceutical companies that need protein-signaling data to guide treatment or development programs. It also has legacy healthcare customers, including patients and payers such as private insurers, government programs, and self-insured employers. Revenue remains very small, so customer concentration and the pace of commercial adoption are important to the business model.
Clinicians and care centers that use Ignite's RPPA data to support cancer treatment decisions.
Drug developers that buy protein-signaling analysis for translational research and development.
Patients and reimbursement sources tied to legacy outpatient and rehabilitation services.
Strategy
Management is focused on funding the growth of its recently acquired laboratory and building out the Ignite Proteomics platform. The company also needs to recruit skilled laboratory and sales personnel while controlling overhead, because commercialization and operating leverage are still early-stage priorities. Preserving liquidity is central, as management has disclosed substantial doubt about going concern and a continuing need for external capital.
The company needs external capital to fund laboratory expansion and ongoing operations.
Revenue is minimal, so adoption of the RPPA platform is essential to create scale.
Laboratory and sales staffing are needed to execute growth and manage overhead.
Geography
IMAC Holdings is headquartered in the United States and its disclosed business activity is overwhelmingly U.S.-based. The available filings do not provide a meaningful country revenue split, but the company’s laboratory, clinical, and payer relationships are tied to U.S. healthcare markets and reimbursement systems. That makes domestic funding access, labor availability, and payer mix more important than international expansion at this stage.
Risks
The company faces going-concern and liquidity risk because it continues to burn cash and depends on external financing to fund operations. Execution risk is also high: the business must recruit specialized staff, scale a recently acquired laboratory, and convert a novel proteomics platform into recurring revenue. Legacy healthcare reimbursement, impairment charges, and legal costs add further volatility to reported results.
Management says additional capital is needed to fund future operations and laboratory growth.
Exposure: Laboratory expansion and ongoing corporate overhead
The company disclosed substantial doubt about its ability to continue as a going concern.
Exposure: Entire business if funding is not secured
Revenue is extremely small, so the RPPA platform must gain market acceptance to scale.
Exposure: Ignite Proteomics revenue growth
The company needs skilled laboratory and sales personnel at acceptable cost.
Exposure: Operating capacity and overhead
Accounting
Judgemental itemsThe company collects from patients, insurers, government programs, and employers, so timing and allowance estimates matter.
Impact: Can affect reported revenue, receivables, and cash flow
A write-off of property and equipment was recorded, showing sensitivity to asset utilization and carrying values.
Impact: Can create sudden losses and reduce asset base
Management has stated substantial doubt about continued operations without new funding.
Impact: Affects investor assessment of liquidity and valuation
Reported results include continuing and discontinued operations, which affects comparability.
Impact: Can make trend analysis of core operations harder
Similar listed companies
Publicly listed companies with a comparable business focus.
Immunome Inc.
IMNM · Pharmaceutical Preparations
Immatics N.V.
IMTX · Biological Products, (No Diagnostic Substances)
Intensity Therapeutics, Inc
INTS · Biological Products, (No Diagnostic Substances)
Onconetix, Inc.
ONCO · Pharmaceutical Preparations
Incyte Corporation
INCY · Services-Commercial Physical & Biological Research
Incyte is a U.S.-based biopharmaceutical company that discovers, develops, and commercializes proprietary medicines.
Immunic, Inc
IMUX · Pharmaceutical Preparations
Last updated: 28/04/2026